Fetal microchimerism has been suggested to play contradictory roles in women’s health, with factors including age of the recipient, time elapsed since microchimerism occurred, and microchimeric cell type modulating disease. Both beneficial and harmful effects have been identified in wound healing and tissue regeneration, immune mediated disease, and cancer. This area of research is relatively new, and hindered by the time course from occurrence of fetal microchimerism to the multi-factorial development of disease. Dogs represent an excellent model for study of fetal microchimerism, as they share our environment, have a naturally condensed lifespan, and spontaneously develop immune-mediated diseases and cancers similar to their human counterparts. However, fetal microchimerism has not been described in dogs. These experiments sought preliminary evidence that dogs develop fetal microchimerism following pregnancy. We hypothesized that Y chromosomal DNA would be detected in the peripheral blood mononuclear cells of female dogs collected within two months of parturition. We further hypothesized that Y chromosomal DNA would be detected in banked whole blood DNA samples from parous female Golden Retrievers with at least one male puppy in a prior litter. Amplification of DNA extracted from five female Golden Retrievers that had whelped within the two months prior to collection revealed strong positive bands for the Y chromosome. Of banked, parous samples, 36% yielded positive bands for the Y chromosome. This is the first report of persistent Y chromosomal DNA in post-partum female dogs and these results suggest that fetal microchimerism occurs in the canine species. Evaluation of the contributions of fetal microchimeric cells to disease processes in dogs as a model for human disease is warranted.
Citation: Axiak-Bechtel SM, Kumar SR, Hansen SA, Bryan JN (2013) Y-chromosome DNA Is Present in the Blood of Female Dogs Suggesting the Presence of Fetal Microchimerism. PLoS ONE 8(7): e68114. doi:10.1371/journal.pone.0068114
Editor: Matthew L. Anderson, Baylor College of Medicine, United States of America
Received: March 7, 2013; Accepted: May 24, 2013; Published: July 8, 2013
Copyright: © 2013 Axiak-Bechtel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors would also like to acknowledge the University of Missouri College of Veterinary Medicine Committee on Research for funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Microchimerism is the co-existence of two cell populations originating from two different persons in the same individual, caused by the transfer of a low number of cells from one person to another in certain circumstances . This can result from blood transfusion, organ transplantation, hematopoietic stem cell transplantation, fraternal twin gestation, or most commonly, pregnancy –. Fetal microchimerism (FMC) is the persistence of fetal cells in maternal organs and circulation as a result of pregnancy. Fetal microchimerism has been reported to have overlapping or even conflicting roles in disease processes. For example, the persistence of fetal cells in maternal organs may lead to a graft versus host reaction, resulting in chronic inflammation, tissue damage, and immune-mediated disease , . Alternatively, these fetal cells have been shown to differentiate into functional immune cells, participate in tissue repair, or provide tumor surveillance. They are thought to have a role in preventing cancer as well as both causing and modulating autoimmune disease –. Unraveling the function of these microchimeric cells is imperative to provide insight into their role in health and disease. Currently, mouse models have identified benefits of induced FMC in chronic disease risk . A naturally occurring, large animal model with risk for spontaneous diseases that frequently affect humans and which have a high frequency of FMC will allow hypothesis testing in a more realistic setting.
Fetal microchimerism is detected in women that have had at least one son by detecting DNA from the Y chromosome. This male chromosomal DNA can be detected within total DNA extracted from circulating peripheral blood mononuclear cells or from whole blood amplified using polymerase chain reaction (PCR) assays. Using these techniques, FMC has been identified following pregnancy in mice, rats, cows, and humans –. Studies are ongoing in women to further elucidate the role of FMC in disease processes. However, these are hindered by the long and challenging process of collecting epidemiologic data on multi-factorial diseases and a lack of repository of blood for research. Companion dogs develop numerous immune-mediated diseases and cancers with etiologies and clinical courses similar to those seen in humans –. The condensed lifespan of dogs make them ideal to model the association of FMC with development of these diseases. Although microchimerism has been described in dogs following organ transplantation and hematopoietic reconstitution, it has not been described in dogs following pregnancy , .
The objective of our study was to determine if Golden Retrievers develop fetal microchimerism following pregnancy. We hypothesized that Y chromosomal DNA would be detected in the peripheral blood mononuclear cells of female dogs whelping male puppies collected within two months of parturition. We further hypothesized that Y chromosomal DNA would be detected in banked whole blood DNA samples from parous Golden Retrievers with at least one male puppy in a prior litter. Confirmation of these hypotheses would support the existence of FMC in dogs. Demonstration of evidence supporting FMC in companion dogs would underpin future research in the mechanisms, selection, persistence, and health effects of FMC. Our results clearly demonstrate the presence of Y chromosomal DNA in female dogs in both the newly-parous and late post-parturient period, suggesting the existence and persistence of FMC in dogs.
Materials and Methods
Collection of Blood Samples and Processing
This protocol was carried out in strict accordance with and approval of the University of Missouri Animal Care and Use Committee (Protocols 7422 and 7360), with informed dog-owner consent. To determine if post-natal FMC occurs in dogs, blood samples were acquired from five female parous dogs within two months of parturition in BD Vacutainer CPT Cell Preparation Tubes with Sodium Citrate anticoagulant with Ficoll-HyPaque media within the tube by collecting veterinarians, with the assistance of the Golden Retriever Club of America. Samples were spun at 1500 g for 30 min to separate mononuclear cells, according to manufacturer instructions, and then shipped on ice to the University of Missouri Comparative Oncology Laboratory. The PBMCs were collected and diluted in phosphate buffered saline (PBS). Genomic DNA was isolated from the cell pellet as described below.
Banked sample DNA was extracted as described below from whole blood digestion and stored for various periods of time. To determine if persistent FMC occurs in dogs, whole blood DNA samples were acquired from the Orthopedic Foundation for Animals (Columbia, MO) from 100 parous golden retrievers selected based on an e-mail survey seeking dogs which had a history of giving birth to litters containing at least one male offspring. Dogs with a history of blood transfusion, a theoretical source of microchimerism, were excluded through the survey. For positive and negative controls, the whole blood sample (∼ 2 ml in heparinized vacutainer tubes) or PBMCs were collected from male and nulliparous female dogs, respectively.
Genomic DNA Isolation
DNA was isolated from the dog blood samples or PBMCs using DNeasy Blood and Tissue Kit (Qiagen, Santa Clarita, CA) according to manufacturer’s instructions. DNA concentration was determined using Nanodrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE).
PCR Assay for Microchimerism
The microchimerism PCR assay was performed as follows: Each DNA preparation (50 ng of male control sample and 100 ng of all female DNA samples) was subjected to a first round of PCR using canine male chromosome (Y) specific primers, followed by a nested amplification of the initial PCR product (50 ng of male control sample was used due to over-amplification of the male control). The primers were designed based on the published sequences of canine male-specific DNA fragments originally detected in Labrador Retrievers . Two sets of primers were synthesized; one set of primers for a 650 bp fragment, and a second set of nested primers within the 650 DNA fragment (∼320 bp fragment). In each PCR run, male and nulliparous female dog DNA was used as positive and negative controls, respectively, with a water control used to detect contamination. The DNA samples from the dogs were subjected to first round of PCR using primers to amplify the 650 bp fragment (native). Typical reactions included HF Phusion buffer (pH 8.0) containing MgCl2, dNTP’s, and Phusion DNA polymerase (Thermo Scientific, Rockford, IL). The PCR conditions were as follows: denaturation at 98°C for 30 s, followed by 28 cycles at 98°C for 20 s, 65°C for 30 s, and then 72°C for 30 s, with a final extension at 72°C for 8 min. For the nested primers, approximately 0.25 µl of the primary reaction sample was used as a template with the internal nested set of primers (320 bp fragment) and further amplified for an additional 10 cycles. In order to visualize the Y-specific bands, an aliquot from each PCR reaction was electrophoresed in a 1% agarose gel in Tris-borate containing Gel-Red (Biotium, Hayward, CA). Gels were photographed on a UV-trans-illuminator (BioDoc-UVA Imaging System, Upland, CA) and bands visualized with ImageJ (http://imagej.nih.gove/ij).
To test the detection sensitivity of the PCR, the male and nulliparous female blood samples were serially diluted in different ratios (male-to-female-1∶1 to 1∶90,000) and genomic DNA was isolated from the mixed samples. The first round of PCR was performed with native primers as mentioned above followed by a second round of PCR using nested primers. The PCR products were visualized using gel electrophoresis as mentioned above.
Gel analysis was performed using ImageJ. Regions of interest were drawn around the region of 320 bp and 1900 bp in each lane and the intensities measured. A ratio of band region to lane background was calculated using the following formula: relative intensity = i320/i1900. Negative control lanes were averaged and the standard deviation calculated. Intensities greater than the mean plus 2 standard deviations were considered to be positive lanes. The positive control bands were significantly more intense than the corresponding regions in the negative control lanes (P<0.001) and all were much greater than the calculated cutoff for positivity. True negative female DNA and water lanes yielded no bands.
Mann-Whitney Rank Sum Test was used to compare groups for difference in relative intensity. Linear correlation was used to compare band intensity to time between previous parturition and blood collection. All evaluations were performed using Sigma-Stat (Systat Software Inc. Chicago, IL). P values <0.05 were considered significant.
The newly parous females were five Golden Retrievers that had whelped a litter containing male puppies in the prior two months. The banked sample population included female Golden Retrievers of varying ages, and the blood collection ranging between a few months to several years after first delivery of their litter.
We optimized the nested PCR assay to increase the sensitivity of our detection and decrease the risk of mispriming with the native primer alone. The outer primer is complementary to dog Y-specific DNA (∼650 bp) and the nested primer (∼320 bp) was designed to be complementary within the 650 bp fragment. The primer sequences are presented in Table 1. The PCR reactions were robust and repeatable (Figure 1A, 1B). DNA from nulliparous females used as a control consistently lacked the target amplicons, confirming the assay specificity for the Y-chromosome.
Amplification of DNA extracted from all five dogs that had whelped within the two months prior to collection uniformly revealed strong positive bands for the Y chromosome (Supplemental data). Ninety banked samples from female Golden Retrievers were tested and 38 samples were positive. However, on further owner questioning, 9 of these 38 positive samples were from dogs which had only whelped litters after blood collection for banking. All nine of these female dogs had male littermates. Therefore, of 81 banked blood DNA samples collected from confirmed parous Golden Retrievers, 29 (36%) yielded positive bands for the Y chromosome. A composite gel for the samples is shown in Figure 2. The relative intensities of the bands are presented in Table 2. From time of whelping to time of banked sample collection varied from three months to eight years. There was no correlation between time from last pregnancy and band intensity. The sensitivity of PCR was also determined. Using nested PCR, bands of Y chromosomal DNA could be detected in 1∶60,000-fold M:F diluted samples, but not in 1∶90,000-fold diluted samples. (Figure 3).
Initial PCR was performed with 650 bp amplicon primers followed by 320 bp nested primer amplification. The PCR products were electrophoresed in a 1% agarose gel with Tri-borate containing Gel-Red and visualized with Bio-Doc-UVA Imaging System. (L) = 100 bp DNA ladder; (+) = male DNA positive control; (−) = female nulliparous DNA negative control; (W) = water template control; (black) numbers = female samples positive for the presence of 320 bp Y-chromosome DNA segments; (gray) numbers = female samples negative for the presence of 320 bp Y-chromosome DNA segments.
Bands of Y chromosomal DNA are detected in as small as 1∶60,000-fold M:F diluted samples, but not in 1∶90,000-fold diluted samples.
Microchimerism was detectable within two months post-whelping in all post-natal dog samples acquired. Persistent Y chromosomal DNA was found in banked samples in 29 of 81 dogs with at least one litter and one male puppy as late as 96 months post-parturition. Y chromosomal DNA detection was sensitive, and bands were detected at 1∶60,000 fold M:F dilutions by PCR, suggesting that as few as one male cell in 60,000 female cells could yield a positive result. These results indicate persistent fetal microchimerism in dogs. The actual rate of microchimerism may be higher, as the assay performed here would not detect female microchimerism.
Dogs, cows, and humans have different types of placentation. Cows have epitheliochorial placentation, with no trophoblast cell invasion beyond the uterine epithelium. Dogs have endotheliochorial placentation, with the uterine epithelium breached and trophoblastic cells in direct contact with endothelial cells of maternal uterine blood vessels. Women have hemochorial placentation, with maternal uterine blood vessels infiltrated by trophoblast cells causing rupture and release of blood into the intervillous space. Despite the difference in the type of placentation and the lack of intimacy between vasculature of the uterus and placenta, fetal microchimerism is still found in the cow , , . The dog has more intimate connections between uterine and fetal vasculature than the cow, therefore, type of placentation is not expected to affect the occurrence of fetal microchimerism.
An email survey of dog owners was used to confirm whelping, parturition date, and sex of puppies. Although recall bias may have occurred when using an email survey, we limited our dogs to purebred Golden Retrievers whose owners participate in the Golden Retriever Club of America. These pet owners keep detailed records on number of pregnancies, parturitions, and sex of puppies for the purposes of pure-bred puppy certification. This record keeping allowed minimization of recall bias.
Retrospectively, nine of the dogs with banked blood samples and a positive result were discovered to be nulliparous at the time of sample collection. The known sources of microchimerism in the dog, organ transplantation and blood transfusion, were ruled out using an owner survey prior to sample analysis. Interestingly, approximately 20% of women with no history of a male birth have male microchimerism in their peripheral blood. Postulated explanations of this phenomenon include early absorbed pregnancy, an unborn male twin, or older male sibling microchimeric cells transferred by maternal circulation to the fetus . All nine nulliparous dogs with circulating Y chromosomal DNA, without a history of whelping, had male littermates. Therefore, in utero sibling microchimerism is a likely mechanism for the Y chromosomal DNA found in these dogs, although other mechanisms cannot be excluded. Given the 100% positivity of dogs with confirmed male offspring within two months post-partum, and 36% of dogs with confirmed male offspring in banked samples, our results strongly support true and persistent fetal microchimerism in the dog.
Detection of the Y chromosome in females with a history of giving birth to male progeny is the most straightforward way to detect and study fetal microchimerism, and was elected as the method of choice in this investigation. More detailed methods in future studies will be undertaken to determine the true cell of origin (fetal versus littermate), female fetal microchimerism, and phenotype of circulating cells.
Companion dogs develop many diseases similar to their human counterpart, and combined with a shared environment and readily available banked blood samples, dogs are an ideal model for human diseases. Furthermore, epidemiologic data collection and interpretation can be obtained much more efficiently due to the condensed lifespan. Immune-mediated disease is common in the pet dog population, including lymphocytic thyroiditis, which parallels Hashimoto’s thyroiditis, and systemic lupus erythematosus , , . Both of these diseases are suspected to be caused, in part, or exacerbated by FMC in women following pregnancy . On the other hand, FMC is thought to have a protective role in cancer formation and prevention. Women with children have a decreased risk of and then a better prognosis for breast cancer and lung cancer, both of which occur spontaneously in dogs , , , . Lymphoma, a systemic immunologic cancer, occurs less commonly in women and intact female dogs compared to men and male dogs or neutered female dogs, respectively . Furthermore, FMC cells may participate in wound healing and may enhance wound healing and tissue regeneration in cases of maternal deficiency , , , . Given these conflicting roles of FMC in women and murine models, it is imperative to define the role of FMC in various disease processes prior to consideration of using FMC in therapy. Many dogs have a traceable lineage, share environmental exposures with humans, and develop multi-factorial diseases which recapitulate their human counterparts , . Straightforward sample collection and similar medical monitoring capabilities in veterinary medicine make companion dogs a very attractive model for further study.
This study demonstrates that persistent male microchimerism of probable fetal origin occurs in the pet dog population. There is evidence in women that FMC may have conflicting roles in disease formation; including the triggering of autoimmune disease as well as protection against cancer and participation in wound healing. The dog represents an excellent model of many ailments in people, and the presence of FMC in dogs will allow studies which further elucidate its role in health and disease.
Gel electrophoresis image showing bands present following amplification using nested primers for 10 rounds of PCR on previously amplified PCR products. Lane 1: ladder, 2: male positive control, 3: female negative control, 4: water control, 5:#4, 6:#5, 7:#21, 8:#22, 9:#23.
Gel electrophoresis image showing bands present following amplification using nested primers for 10 rounds of PCR on previously amplified PCR products. Top Half: Lane 1: ladder, 2: male positive control, 3: female negative control, 4: water control, 5:#1, 6:#2, 7:#3, 8:#5, 9:#6. Bottom Half: Lane 1: ladder, 2:#7, 3:#8, 4:#9, 5:#10, 6:#11, 7:#12, 8:#13, 9:#20.
Gel electrophoresis image showing bands present following amplification using nested primers for 10 rounds of PCR on previously amplified PCR products. Top Half: Lane 1:ladder, 2:male positive control, 3:female negative control, 4:water control, 5:#14, 6:#15, 7:#16, 8:#17, 9:#18, 10:#19, 11:#20. Bottom Half: Lane 1:ladder, 2:#24, 3:#25, 4:#26, 5:#27, 6:#28, 7:#29, 8:#30, 9:#31, 10:#32, 11:#33.
Gel electrophoresis image showing bands present following amplification using nested primers for 10 rounds of PCR on previously amplified PCR products. Top Half: Lane 1:ladder, 2:male positive control, 3:female negative control, 4:water control, 5:#34, 6:#35, 7:#36, 8:#37, 9:#38, 10:#39, 11:#40. Bottom Half: Lane 1: ladder, 2:male positive control, 3:#41, 4:#42, 5:#43, 6:#44, 7:#45.
Gel electrophoresis image showing bands present following amplification using nested primers for 10 rounds of PCR on previously amplified PCR products. Top Half: Lane 1:ladder, 2:male positive control, 3:female negative control, 4:water control, 5:#47, 6:#48, 7:#49, 8:#50, 9:#51, 10:#52, 11:#53. Bottom Half: Lane 1:ladder, 2:#54, 3:#55, 4:#56, 5:#57, 6:#58, 7:#59, 8:#60, 9:#61, 10:#62, 11:#63.
Gel electrophoresis image showing bands present following amplification using nested primers for 10 rounds of PCR on previously amplified PCR products. Top Half: Lane 1: ladder, 2:male positive control, 3:female negative control, 4:water control, 5:#64, 6:#65, 7:#66, 8:#67, 9:#68, 10:#69, 11:#70. Bottom Half: Lane 1: ladder, 2:#71, 3:#72, 4:#73, 5:#74, 6:#75, 7:#76, 8:#77, 9:#78, 10:#79, 11:#80.
Gel electrophoresis image showing bands present following amplification using nested primers for 10 rounds of PCR on previously amplified PCR products. Top Half: Lane 1: ladder, 2:male positive control, 3:female negative control, 4:water control, 5:#81, 6:#82, 7:#83, 8:#84, 9:#85, 10:#86, 11:#87. Bottom Half: Lane 1: ladder, 2:male positive control, 3:#88, 4:#89, 5:#90, 6:blank, 7:blank.
The authors would like to acknowledge the Golden Retriever Club of America, the Orthopedic Foundation for Animals, the CHIC DNA Repository, and Amanda Bolyard, DVM for their assistance with sample acquisition.
Conceived and designed the experiments: JNB SRK SMA. Performed the experiments: SRK SAH. Analyzed the data: JNB SRK SAH SMA. Wrote the paper: SMA SRK JNB.
- 1. Fugazzola L, Cirello V, Beck-Peccoz P (2011) Fetal microchimerism as an explanation of disease. Nat Rev Endocrinol 7: 89–97.
- 2. Liegeois A, Escourrou J, Ouvre E, Charreire J (1977) Microchimerism: a stable state of low-ratio proliferation of allogeneic bone marrow. Transplant Proc 9: 273–276.
- 3. Stikvoort A, Gertow J, Sundin M, Remberger M, Mattsson J, et al. (2013) Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients. Biol Blood Marrow Transplant 19: 838–844.
- 4. Nassar D, Droitcourt C, Mathieu-d’Argent E, Kim MJ, Khosrotehrani K, et al. (2012) Fetal progenitor cells naturally transferred through pregnancy participate in inflammation and angiogenesis during wound healing. FASEB J 26: 149–157.
- 5. Boyon C, Collinet P, Boulanger L, Rubod C, Lucot JP, et al. (2011) Fetal microchimerism: benevolence or malevolence for the mother? Eur J Obstet Gynecol Reprod Biol 158: 148–152.
- 6. Kallenbach LR, Johnson KL, Bianchi DW (2011) Fetal cell microchimerism and cancer: a nexus of reproduction, immunology, and tumor biology. Cancer Res 71: 8–12.
- 7. Gadi VK, Nelson JL (2007) Fetal microchimerism in women with breast cancer. Cancer Res 67: 9035–9038.
- 8. Gadi VK, Malone KE, Guthrie KA, Porter PL, Nelson JL (2008) Case-control study of fetal microchimerism and breast cancer. PLoS One 3: e1706.
- 9. Cirello V, Perrino M, Colombo C, Muzza M, Filopanti M, et al. (2010) Fetal cell microchimerism in papillary thyroid cancer: studies in peripheral blood and tissues. Int J Cancer 126: 2874–2878.
- 10. Wang Y, Iwatani H, Ito T, Horimoto N, Yamato M, et al. (2004) Fetal cells in mother rats contribute to the remodeling of liver and kidney after injury. Biochem Biophys Res Commun 325: 961–967.
- 11. Jayaraman S, Patel T, Patel V, Ajani S, Garza R, et al. (2010) Transfusion of nonobese diabetic mice with allogeneic newborn blood ameliorates autoimmune diabetes and modifies the expression of selected immune response genes. J Immunol 184: 3008–3015.
- 12. Turin L, Invernizzi P, Woodcock M, Grati FR, Riva F, et al. (2007) Bovine fetal microchimerism in normal and embryo transfer pregnancies and its implications for biotechnology applications in cattle. Biotechnol J 2: 486–491.
- 13. Turin L, Tribbioli G, Invernizzi P, Grati FR, Crema S, et al. (2007) Fetal microchimerism in normal and embryo transfer bovine pregnancies. Vet Res Commun 31 Suppl 1205–207.
- 14. Lee TH, Montalvo L, Chrebtow V, Busch MP (2001) Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41: 276–282.
- 15. Smid M, Lagona F, de Benassuti L, Ferrari A, Ferrari M, et al. (1999) Evaluation of different approaches for fetal DNA analysis from maternal plasma and nucleated blood cells. Clin Chem 45: 1570–1572.
- 16. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, et al. (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350: 485–487.
- 17. Houfflin-Debarge V, O’Donnell H, Overton T, Bennett PR, Fisk NM (2000) High sensitivity of fetal DNA in plasma compared to serum and nucleated cells using unnested PCR in maternal blood. Fetal Diagn Ther 15: 102–107.
- 18. Lo YM (2000) Fetal DNA in maternal plasma: biology and diagnostic applications. Clin Chem 46: 1903–1906.
- 19. Fleming JM, Creevy KE, Promislow DE (2011) Mortality in north american dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death. J Vet Intern Med 25: 187–198.
- 20. Fournel C, Chabanne L, Caux C, Faure JR, Rigal D, et al. (1992) Canine systemic lupus erythematosus. I: A study of 75 cases. Lupus 1: 133–139.
- 21. Graham PA, Nachreiner RF, Refsal KR, Provencher-Bolliger AL (2001) Lymphocytic thyroiditis. Vet Clin North Am Small Anim Pract 31: 915–933, vi-vii.
- 22. Hansen K, Khanna C (2004) Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 40: 858–880.
- 23. Rowell JL, McCarthy DO, Alvarez CE (2011) Dog models of naturally occurring cancer. Trends Mol Med 17: 380–388.
- 24. Graves SS, Hogan WJ, Kuhr C, Diaconescu R, Harkey M, et al. (2008) Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism. Biol Blood Marrow Transplant 14: 1201–1208.
- 25. Cain GR, Champlin RE (1989) Long-term complete chimerism and stable hematopoiesis in beagles after fetal liver hematopoietic stem cell transplantation. Am J Vet Res 50: 1282–1284.
- 26. Olivier M, Lust G (1998) Two DNA sequences specific for the canine Y chromosome. Anim Genet 29: 146–149.
- 27. Moffett A, Loke C (2006) Immunology of placentation in eutherian mammals. Nat Rev Immunol 6: 584–594.
- 28. Yan Z, Lambert NC, Guthrie KA, Porter AJ, Loubiere LS, et al. (2005) Male microchimerism in women without sons: quantitative assessment and correlation with pregnancy history. Am J Med 118: 899–906.
- 29. Kennedy LJ, Quarmby S, Happ GM, Barnes A, Ramsey IK, et al. (2006) Association of canine hypothyroidism with a common major histocompatibility complex DLA class II allele. Tissue Antigens 68: 82–86.
- 30. Fugazzola L, Cirello V, Beck-Peccoz P (2012) Microchimerism and endocrine disorders. J Clin Endocrinol Metab 97: 1452–1461.
- 31. O’Donoghue K, Sultan HA, Al-Allaf FA, Anderson JR, Wyatt-Ashmead J, et al. (2008) Microchimeric fetal cells cluster at sites of tissue injury in lung decades after pregnancy. Reprod Biomed Online 16: 382–390.
- 32. Dubernard G, Oster M, Chareyre F, Antoine M, Rouzier R, et al. (2009) Increased fetal cell microchimerism in high grade breast carcinomas occurring during pregnancy. Int J Cancer 124: 1054–1059.
- 33. Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, et al. (2009) Hormonal and sex impact on the epidemiology of canine lymphoma. J Cancer Epidemiol 2009: 591753.
- 34. Nelson JL (2012) The otherness of self: microchimerism in health and disease. Trends Immunol 33: 421–427.
- 35. Lee ES, Bou-Gharios G, Seppanen E, Khosrotehrani K, Fisk NM (2010) Fetal stem cell microchimerism: natural-born healers or killers? Mol Hum Reprod 16: 869–878.